Olaparib

Olaparib (AZD-2281, trade name Lynparza) is an FDA-approved targeted therapy for cancer, developed by KuDOS Pharmaceuticals and later by AstraZeneca. It is a PARP inhibitor, inhibiting poly ADP ribose polymerase (PARP), an enzyme involved in DNA repair. It acts against cancers in people with hereditary BRCA1 or BRCA2 mutations, which include some ovarian, breast, and prostate cancers.

 COA of our Olaparib

Item	Specifications	Analysis Results	Conclusion
Appearance	Light yellow solid	Light yellow solid	conform
HNMR	Comply with the structure	Comply with the structure	Conform
LC-MS	Comply with the structure	Comply with the structure	Conform
Purity	≥95%	99.1%(254nm) 99.4%(220nm)	Conform Conform
Melting point	N/A	N/A	N/A

my contact infomation is:

Whatsapp: 008615032102186

Email: bettyapi1989@163.com 

Notice: This product is only suitable for laboratory use, or the use of animals. It can not be used directly on the human body